ribosomal modification protein rimK like family member AGenealiases: FAM80A · NAAGS · NAAGS-II · NAAGS2
Q-omics provides the consensus-scored RIMKLA profile across patient tissues and cancer cell-line models. RIMKLA expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RIMKLA is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, RIMKLA RNA expression shows 19,119 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, and KIRP as cancer lineages where RIMKLA shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RIMKLA — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RIMKLA survival associations across molecular data types. RIMKLA RNA expression shows survival associations in the most cancer types (19), followed by mutation status (6) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RIMKLA RNA expression–survival associations across cancer types. High RIMKLA expression shows unfavorable associations in ESCA, DLBC and THCA, but favorable associations in KIRC, LUAD and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RIMKLA RNA expression.
This table summarizes RIMKLA tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RIMKLA. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RIMKLA shows lower tumor expression in THCA, KICH, COAD and LUSC and higher tumor expression in KIRC and KIRP. The KIRC box plot shows higher RIMKLA RNA expression in tumor versus normal tissue (log2 FC = +1.975, t-test p < 0.001).
This table shows molecular features associated with RIMKLA in patient tissues and cancer cell lines. In patient samples, RIMKLA shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, RIMKLA RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and LUNG_SCLC.
